banner

Norfolk Southern Orders PbC Batteries for Locomotive Switcher from Axion Power

Axion Power International (AXPW)

Axion Power International Inc. (OTCBB: AXPW), the developer of advanced lead­carbon PbC® batteries and energy storage systems, announced that it has received an order from Norfolk Southern Corp. (NYSE: FSC) for PbC batteries for use in a battery-powered locomotive.  Axion said this first $400,000 purchase order is part of a $475,000 total purchase order to be shipped and deployed over the next three to four months that will be used in the commissioning of Norfolk Southern’s NS-999.  To date, this is the largest single PbC battery order that Axion has received. No further details were disclosed.

“We have been working with Norfolk Southern for two and a half years, and we are very pleased that this first hybrid ‘switcher’ yard locomotive, to be run completely on PbC batteries, will soon be in service,” said Axion Power Chairman & CEO Thomas Granville.



A yard switcher locomotive is used in a train yard to assemble and disassemble long trip over-the-road trains as well as for general movement of railroad cars around the rail yard.

According to the Axion chief, the companies are working together to deploy the first “over the road” locomotive powered by Axion batteries.  The larger unit will require approximately twice the number of 100-percent recyclable batteries as the yard switcher.

“High-performance PbC batteries are ideally suited for hybrid locomotive applications due to their high charge acceptance, fast charge and discharge capabilities (important in regenerative braking), and their inherent ability to equalize voltage when utilized in large string configurations,” explained Granville.

Shares of AXPW are holding an uptrend in 2012; closing 2011 at 27 cents before surging to 64 cents late in January.  Shares cooled from the highs, but are still holding support above a 37 cent support level with yesterday’s close at 43 cents.

Axion Power (AXPW) Stock Quote and News:







Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally – and taking the headline – the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more
banner

Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.